Organization | University of Memphis

University of Memphis Report issue

Academic/Hospital Phase 2 Phase 4

Founded: Memphis TN United States (1912)

Organization Overview

First Clinical Trial

2003

NCT00403312

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Principal Investigator, School of Health Studies | The University of Memphis | University of Memphis

Active Ingredients

Drugs in Phase 4 Trials (3)

ketamine (ketalar) (1 trial)

morphine (1 trial)

sodium chloride (1 trial)

Drugs in Phase 2 Trials (1)

nicotine (nicorette) (2 trials)

Drugs in Other Trials (10)

1,3-dimethylamylamine (1 trial)

aloe vera (2 trials)

bone morphogenetic protein-2 (1 trial)

caffeine (1 trial)

cherry (2 trials)

coconut oil (1 trial)

icosapent ethyl (vascepa) (1 trial)

krill oil (1 trial)

lactobacillus plantarum (1 trial)

solarplast (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acute Pain (Phase 4)

Emergencies (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 15
# of Trial APIs: 14